$CRMD
CorMedix Inc.

2023 Q4 Form 10-Q Financial Statement

#000121390023086981 Filed on November 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $0.00 $6.817K
YoY Change -100.0% -82.1%
Cost Of Revenue $0.00 $1.469K
YoY Change -100.0% -94.16%
Gross Profit $0.00 $5.348K
YoY Change -100.0% -58.61%
Gross Profit Margin 78.45%
Selling, General & Admin $13.38M $7.803M $4.628M
YoY Change 139.98% 68.61% 20.63%
% of Gross Profit 86537.28%
Research & Development $2.289M $2.664M $2.339M
YoY Change -19.5% 13.88% -50.66%
% of Gross Profit 43740.99%
Depreciation & Amortization $18.67K $20.00K $21.28K
YoY Change -17.1% -6.02% 21.18%
% of Gross Profit 397.91%
Operating Expenses $15.67M $10.47M $6.967M
YoY Change 86.12% 50.23% -18.78%
Operating Profit -$15.67M -$10.47M -$6.962M
YoY Change 86.77% 50.35% -18.72%
Interest Expense $914.7K $13.11K $8.776K
YoY Change 407.41% 49.42% -297.21%
% of Operating Profit
Other Income/Expense, Net $722.9K $108.2K
YoY Change 568.06% -2533.39%
Pretax Income -$14.75M -$9.740M -$6.854M
YoY Change 79.73% 42.11% -20.02%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$14.75M -$9.744M -$6.854M
YoY Change 79.73% 42.18% -20.02%
Net Earnings / Revenue -100538.67%
Basic Earnings Per Share -$0.17 -$0.17
Diluted Earnings Per Share -$0.26 -$0.17 -$0.17
COMMON SHARES
Basic Shares Outstanding 54.81M shares 54.81M shares 41.11M shares
Diluted Shares Outstanding 56.55M shares 41.18M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.03M $86.59M $59.00M
YoY Change 29.32% 46.76% -18.02%
Cash & Equivalents $43.64M $53.31M $43.25M
Short-Term Investments $32.39M $33.27M $15.75M
Other Short-Term Assets $1.313M $2.470M $663.6K
YoY Change 73.07% 272.2% -31.75%
Inventory $2.106M $269.00
Prepaid Expenses $353.6K $1.255M $19.12K
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $79.45M $89.06M $59.66M
YoY Change 33.42% 49.27% -18.26%
LONG-TERM ASSETS
Property, Plant & Equipment $1.866M $1.589M $1.503M
YoY Change 15.94% 5.69% -34.53%
Goodwill
YoY Change
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $103.1K $100.0K $102.3K
YoY Change 0.72% -2.26% 0.01%
Total Long-Term Assets $2.610M $2.367M $2.413M
YoY Change 4.92% -1.9% 0.59%
TOTAL ASSETS
Total Short-Term Assets $79.45M $89.06M $59.66M
Total Long-Term Assets $2.610M $2.367M $2.413M
Total Assets $82.06M $91.43M $62.08M
YoY Change 32.27% 47.28% -17.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.280M $2.386M $1.767M
YoY Change 94.34% 35.01% 59.67%
Accrued Expenses $6.970M $5.138M $3.163M
YoY Change 75.4% 62.43% -22.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.40M $7.671M $5.062M
YoY Change 80.65% 51.54% -2.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $517.0K $560.0K $703.0K
YoY Change -22.56% -20.34% -15.71%
Total Long-Term Liabilities $517.0K $560.0K $703.0K
YoY Change -22.56% -20.34% -15.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.40M $7.671M $5.062M
Total Long-Term Liabilities $517.0K $560.0K $703.0K
Total Liabilities $11.92M $8.227M $5.765M
YoY Change 70.77% 42.71% -4.64%
SHAREHOLDERS EQUITY
Retained Earnings -$321.7M -$306.9M -$267.2M
YoY Change 16.83% 14.9%
Common Stock $54.94K $54.81K $41.21K
YoY Change 28.31% 33.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $70.14M $83.20M $56.31M
YoY Change
Total Liabilities & Shareholders Equity $82.06M $91.43M $62.08M
YoY Change 32.27% 47.28% -17.66%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$14.75M -$9.744M -$6.854M
YoY Change 79.73% 42.18% -20.02%
Depreciation, Depletion And Amortization $18.67K $20.00K $21.28K
YoY Change -17.1% -6.02% 21.18%
Cash From Operating Activities -$10.75M -$8.690M -$5.995M
YoY Change 74.59% 44.94% 8.94%
INVESTING ACTIVITIES
Capital Expenditures $295.9K $10.00K -$76.42K
YoY Change 129.85% -113.09% -90.18%
Acquisitions
YoY Change
Other Investing Activities $893.7K -$580.0K -$37.87K
YoY Change 604.27% 1431.56% -92.33%
Cash From Investing Activities $597.8K -$590.0K -$114.3K
YoY Change -32239.25% 416.28% -91.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 467.6K 42.90M 437.3K
YoY Change -92.26% 9710.42%
NET CHANGE
Cash From Operating Activities -10.75M -8.690M -5.995M
Cash From Investing Activities 597.8K -590.0K -114.3K
Cash From Financing Activities 467.6K 42.90M 437.3K
Net Change In Cash -9.680M 33.62M -5.672M
YoY Change 8611.53% -692.69% -16.27%
FREE CASH FLOW
Cash From Operating Activities -$10.75M -$8.690M -$5.995M
Capital Expenditures $295.9K $10.00K -$76.42K
Free Cash Flow -$11.04M -$8.700M -$5.919M
YoY Change 75.72% 46.98% 25.25%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Revenues
Revenues
usd
us-gaap Gross Profit
GrossProfit
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39741555 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41183585 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48715585 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34673
dei Entity Registrant Name
EntityRegistrantName
CORMEDIX INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5894890
dei Entity Address Address Line1
EntityAddressAddressLine1
300 Connell Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 4200
dei Entity Address City Or Town
EntityAddressCityOrTown
Berkeley Heights
dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07922
dei City Area Code
CityAreaCode
(908)
dei Local Phone Number
LocalPhoneNumber
517-9500
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
dei Trading Symbol
TradingSymbol
CRMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
54812042 shares
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53313811 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43148323 usd
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
84546 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
124102 usd
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
33273259 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
15644062 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1255105 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11016 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1135656 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
623672 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
89062377 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
59551175 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1588963 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1609679 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
102664 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
102320 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
675116 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
775085 usd
CY2023Q3 us-gaap Assets
Assets
91429120 usd
CY2022Q4 us-gaap Assets
Assets
62038259 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2386108 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2202149 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5138243 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3973941 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
146531 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
134801 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7670882 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6310891 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
556416 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
667632 usd
CY2023Q3 us-gaap Liabilities
Liabilities
8227298 usd
CY2022Q4 us-gaap Liabilities
Liabilities
6978523 usd
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
181622 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
181622 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
181622 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
181622 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
182 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
182 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
160000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
54812042 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
54812042 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42815196 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42815196 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
54813 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
42815 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
84399 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
82743 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
390008412 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
330294782 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-306945984 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-275360786 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
83201822 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
55059736 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91429120 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62038259 usd
CY2022Q3 us-gaap Revenues
Revenues
6817 usd
us-gaap Revenues
Revenues
35706 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
1469 usd
us-gaap Cost Of Revenue
CostOfRevenue
3328 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
5348 usd
us-gaap Gross Profit
GrossProfit
32378 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2663976 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2339268 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10866236 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7836327 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7803307 usd
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4628014 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22422808 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14430791 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
10467283 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
6967282 usd
us-gaap Operating Expenses
OperatingExpenses
33289044 usd
us-gaap Operating Expenses
OperatingExpenses
22267118 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10467283 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6961934 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-33289044 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-22234740 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
765241 usd
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
93417 usd
us-gaap Interest Income Other
InterestIncomeOther
1761808 usd
us-gaap Interest Income Other
InterestIncomeOther
142511 usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-29199 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
23572 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-30222 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
31598 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
13113 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
8776 usd
us-gaap Interest Expense
InterestExpense
27740 usd
us-gaap Interest Expense
InterestExpense
17740 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
722929 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
108213 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1703846 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
156369 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-9744354 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-6853721 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-31585198 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-22078371 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-585617 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9744354 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6853721 usd
us-gaap Net Income Loss
NetIncomeLoss
-31585198 usd
us-gaap Net Income Loss
NetIncomeLoss
-21492754 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-4571 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
15811 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
1090 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
-19677 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-1727 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-9558 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
566 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-21681 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6298 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6253 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1656 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-41358 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9750652 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6847468 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31583542 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21534112 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56553174 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41183585 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48715585 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39741555 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
49051109 usd
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
42878399 usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20132 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1002834 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6298 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9744354 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
83201822 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
55059736 usd
crmd Stockissuedinconnectionwith At Msaleofcommonstocknet
StockissuedinconnectionwithATMsaleofcommonstocknet
12515209 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
42878399 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
253988 usd
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-198442 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4276474 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1656 usd
us-gaap Net Income Loss
NetIncomeLoss
-31585198 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
83201822 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
61738740 usd
CY2022Q3 crmd Stockissuedinconnectionwith At Msaleofcommonstocknet
StockissuedinconnectionwithATMsaleofcommonstocknet
308665 usd
CY2022Q3 crmd Stock Issued In Connection With Warrants Exercised Cash
StockIssuedInConnectionWithWarrantsExercisedCash
128625 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
983524 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
6253 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6853721 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
56312086 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
62798067 usd
crmd Stockissuedinconnectionwith At Msaleofcommonstocknet
StockissuedinconnectionwithATMsaleofcommonstocknet
11724037 usd
crmd Stock Issued In Connection With Warrants Exercised Cash
StockIssuedInConnectionWithWarrantsExercisedCash
128625 usd
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3195469 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-41358 usd
us-gaap Net Income Loss
NetIncomeLoss
-21492754 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
56312086 usd
us-gaap Net Income Loss
NetIncomeLoss
-31585198 usd
us-gaap Net Income Loss
NetIncomeLoss
-21492754 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4276474 usd
us-gaap Share Based Compensation
ShareBasedCompensation
3195469 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
99970 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
92559 usd
us-gaap Depreciation
Depreciation
52085 usd
us-gaap Depreciation
Depreciation
62102 usd
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-42583 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2739 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1756105 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-271932 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
183903 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-441319 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1164571 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
154588 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-99486 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-89792 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27663786 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18201893 usd
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
60978108 usd
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
22366898 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
43350000 usd
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
18750000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31369 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
90605 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-17659477 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3707503 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12515209 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11724037 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
198442 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
42878399 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
128625 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
253988 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55449154 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11852662 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
385 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-24464 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10126276 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-10081198 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43374745 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53551277 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
53501021 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43470079 usd
us-gaap Interest Paid Net
InterestPaidNet
27739 usd
us-gaap Interest Paid Net
InterestPaidNet
17740 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1090 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-19677 usd
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-28
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
18700000 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
104000000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Use of Estimates</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p>
crmd Maximum Aggregate Amount Of Cash Payments Due Upon Achievement Of Milestones
MaximumAggregateAmountOfCashPaymentsDueUponAchievementOfMilestones
3000000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53313811 usd
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
43254116 usd
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
187210 usd
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
215963 usd
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
53501021 usd
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
43470079 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
39329961 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1213 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1700 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
39330448 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
22956564 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4140 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3537 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
22955961 usd
crmd Balance Of Cash Payments Due Upon Achievement Of Milestones
BalanceOfCashPaymentsDueUponAchievementOfMilestones
2500000 usd
crmd License Agreement May Be Terminated By Company Basis Upon60 Days Prior Written Notice
LicenseAgreementMayBeTerminatedByCompanyBasisUpon60DaysPriorWrittenNotice
P60D
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2500625 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11428673 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10218722 shares
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
104400000 usd
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7500000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1500093 shares
CY2023Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5600000 usd
CY2022Q3 crmd Stockissuedinconnectionwith At Msalesofcommonstocknet
StockissuedinconnectionwithATMsalesofcommonstocknet
76933 shares
crmd Stockissuedinconnectionwith At Msalesofcommonstocknet
StockissuedinconnectionwithATMsalesofcommonstocknet
3097273 shares
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1256820 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
514354 usd
CY2023Q3 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
2914962 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
2180581 usd
CY2023Q3 crmd Manufacturing Development Current
ManufacturingDevelopmentCurrent
911698 usd
CY2022Q4 crmd Manufacturing Development Current
ManufacturingDevelopmentCurrent
1214550 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
54763 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
64456 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5138243 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3973941 usd
CY2022Q4 crmd Number Of Legal Actions Filed
NumberOfLegalActionsFiled
2 pure
CY2023Q4 crmd Security Deposit Remaining
SecurityDepositRemaining
10000 eur
CY2023Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
80000 eur
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
46000 eur
us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
49000 usd
crmd Accruals Legal Settlements
AccrualsLegalSettlements
38000 eur
crmd Accruals Legal Settlements
AccrualsLegalSettlements
40000 usd
crmd Legal Settlement Arguing Amount To Be Paid
LegalSettlementArguingAmountToBePaid
38000 eur
crmd Defendant Requested The Amount Of The Cost To Be Paid
DefendantRequestedTheAmountOfTheCostToBePaid
46000 eur
CY2023Q3 crmd Court Decided To Reimbursed Amount Of The Defendant
CourtDecidedToReimbursedAmountOfTheDefendant
38000 eur
CY2023Q3 us-gaap Security Deposit
SecurityDeposit
116000 eur
CY2023Q4 us-gaap Proceeds From Legal Settlements
ProceedsFromLegalSettlements
10000 eur
CY2023Q4 us-gaap Proceeds From Legal Settlements
ProceedsFromLegalSettlements
11000 usd
crmd Amount Of Initial Licensing Fee
AmountOfInitialLicensingFee
325000 usd
crmd Shares Of Equity Of Common Stock
SharesOfEquityOfCommonStock
7996 shares
us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
29109 shares
CY2014 crmd Number Of Shares Released In Escrow
NumberOfSharesReleasedInEscrow
7277 shares
crmd Number Of Share Held In Escrow Of Common Stock
NumberOfShareHeldInEscrowOfCommonStock
21832 shares
CY2022Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
300000 usd
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M17D
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
181622 shares
CY2023Q3 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
21291665 usd
CY2023Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6500000 usd
us-gaap Insured Financial Obligations With Credit Deterioration Remaining Weighted Average Contract Period
InsuredFinancialObligationsWithCreditDeteriorationRemainingWeightedAverageContractPeriod
P1Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0498 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0369 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.43
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2020Q3 us-gaap Payments For Leasing Costs
PaymentsForLeasingCosts
17000 usd
CY2023Q3 crmd Rental Agreement Expense
RentalAgreementExpense
400 eur
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
52000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
155000 usd
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
52000 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
157000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
703000 usd
crmd Operating Lease Liabilities Shortterm
OperatingLeaseLiabilitiesShortterm
147000 usd
CY2023Q3 crmd Operating Lease Liabilities Net Of Current Portion
OperatingLeaseLiabilitiesNetOfCurrentPortion
556000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
803000 usd
CY2022 crmd Operating Lease Liabilities Shortterm
OperatingLeaseLiabilitiesShortterm
135000 usd
CY2022Q4 crmd Operating Lease Liabilities Net Of Current Portion
OperatingLeaseLiabilitiesNetOfCurrentPortion
668000 usd
CY2023Q3 crmd Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
675000 usd
CY2022Q4 crmd Operating Lease Right Of Use Assets
OperatingLeaseRightOfUseAssets
775000 usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
50000 usd
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
50000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
150000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
150000 usd
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09 pure
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.09 pure
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
51000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
205000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
208000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
211000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
169000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
844000 usd
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
141000 usd
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
703000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56553174 shares
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001410098

Files In Submission

Name View Source Status
0001213900-23-086981-index-headers.html Edgar Link pending
0001213900-23-086981-index.html Edgar Link pending
0001213900-23-086981.txt Edgar Link pending
0001213900-23-086981-xbrl.zip Edgar Link pending
crmd-20230930.xsd Edgar Link pending
f10q0923ex31-1_cormedix.htm Edgar Link pending
f10q0923ex31-2_cormedix.htm Edgar Link pending
f10q0923ex32-1_cormedix.htm Edgar Link pending
f10q0923ex32-2_cormedix.htm Edgar Link pending
f10q0923_cormedix.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
crmd-20230930_cal.xml Edgar Link unprocessable
crmd-20230930_def.xml Edgar Link unprocessable
crmd-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
crmd-20230930_lab.xml Edgar Link unprocessable
f10q0923_cormedix_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending